Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NI02
- Development stage
- Preclinical
- Lead developer
- Amprologix
- Modality
- Peptides
01
Overview
NI02 is an experimental antimicrobial peptide (AMP) being developed by Amprologix for the treatment of dermatitis and *Clostridioides difficile* (C. difficile) infections. As part of Amprologix's pipeline of peptide-based antibiotics, NI02 is designed to address the growing challenge of antimicrobial resistance (AMR). The compound is currently in the discovery and in vitro screening stages of preclinical development. While it is characterized as a bactericidal peptide, its specific molecular targets and mechanism of action have not been publicly disclosed. The development of NI02 follows the company's focus on utilizing AI-generated and naturally derived peptides to create novel anti-infective therapies.
Beyond the preview
Go deeper on NI02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NI02.